ISRCTN19844007 https://doi.org/10.1186/ISRCTN19844007

# Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

**Submission date**
29/09/2006

**Registration date**
29/09/2006

**Last Edited**
17/05/2017

**Recruitment status**
No longer recruiting

**Overall study status**
Completed

**Condition category**
Haematological Disorders

[ ] Prospectively registered
[ ] Protocol
[ ] Statistical analysis plan
[ ] Results
[ ] Individual participant data
[ ] Record updated in last year

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr A Chesser

**Contact details**
Consultant Nephrologist
Renal Office
Royal London Hospital
Whitechapel
London
United Kingdom
E1 1BB
+44 (0)20 7377 7366
alistair.chesser@bartsandthelondon.nhs.uk

## Additional identifiers

### Protocol serial number
N0205168926

# Study information

### Scientific Title
Use of erythropoietin for anaemia management, clearance of low and middle molecular weight uraemic toxins, quality of life and cost effectiveness of mid-dilution on-line haemodiafiltration compared to conventional low flux haemodialysis

### Study objectives
To quantify the effect of on-line mid-dilution haemodiafiltration on the use of erythropoietin for anaemia management in patients with end-stage renal disease compared to the technique of conventional haemodialysis.

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Study design
Randomised controlled trial

### Primary study design
Interventional

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Anaemia

### Interventions
Not provided at time of registration

### Intervention Type
Drug

### Phase
Not Applicable

### Drug/device/biological/vaccine name(s)
Erythropoietin

### Primary outcome(s)
Control of haemoglobin and use of erythropoietin

### Key secondary outcome(s))
Not provided at time of registration

**Completion date**
31/07/2007

# Eligibility

**Key inclusion criteria**
Not provided at time of registration

**Participant type(s)**
Patient

**Healthy volunteers allowed**
No

**Age group**
Not Specified

**Sex**
Not Specified

**Key exclusion criteria**
Not provided at time of registration

**Date of first enrolment**
27/07/2005

**Date of final enrolment**
31/07/2007

# Locations

**Countries of recruitment**
United Kingdom

England

**Study participating centre**
**Royal London Hospital**
London
United Kingdom
E1 1BB

# Sponsor information

**Organisation**
Record Provided by the NHSTCT Register - 2006 Update - Department of Health (UK)

# Funder(s)

**Funder type**
Government

**Funder Name**
Barts and The London NHS Trust (UK)

**Funder Name**
NHS R&D Support Funding (UK)

# Results and Publications

## Individual participant data (IPD) sharing plan

**IPD sharing plan summary**
Not provided at time of registration

**Study outputs**

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |